(Boursier.com) — Lysogen a phase 3 biopharmaceutical company based on a gene therapy technology platform targeting diseases of the central nervous system (CNS), announces that it has requested, together with the receiver, the conversion of the safeguard procedure, of which it is the object since December 13, in receivership proceedings.
The Commercial Court of Nanterre will rule on this request in the coming days.
This conversion request is based on the fact that the safeguard procedure did not identify a solution to consolidate Lysogene’s financial situation and sustain its funding horizon.
The conversion of the safeguard procedure into receivership will allow Lysogene to continue to seek solutions to sustain the pursuit of its activities and to conduct a search for a buyer or investor.
In this context, a call for tenders for the purpose of finding buyers or investors will be published today. The deadline for submitting takeover bids was set by the court-appointed administrator at 15 February 2023 at 12 noon.
©2023 Boursier.com